|
Association of pancreatic adenocarcinoma location (head/body/tail) with DDR mutation status and response to platinum-based therapy. |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Perthera |
Patents, Royalties, Other Intellectual Property - Perthera |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Johnson & Johnson (I) |
Research Funding - Abbvie; Astellas Pharma; Boston Biomedical; Merck; Peloton Therapeutics; Tyme |
|
|
Consulting or Advisory Role - AstraZeneca; Basilea; Boehringer Ingelheim; Exelixis; Genentech; Helsinn Therapeutics; Incyte; Merck; QED Therapeutics; SERVIER; Taiho Pharmaceutical |
Speakers' Bureau - Helsinn Therapeutics; SERVIER |
Research Funding - Bayer; Bristol-Myers Squibb; Exelixis; Immunovaccine; Loxo/Lilly; Merck; Novocure; Nucana; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen; Taiho Pharmaceutical |
|
|
|
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Cor2Ed |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Z and L International Medical |
Consulting or Advisory Role - Alphamab; Ambrx; AstraZeneca; Biosynergies; Coherent; datarevive; Foundation Medicine; Johnson & Johnson/Janssen; Merck; Merrimack; Mingruizhiyao; NovaGenesis; novarock |
Research Funding - Amgen; AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Gradalis; Halozyme; InxMed; ITeos Therapeutics; Merck; NovaRock |
Patents, Royalties, Other Intellectual Property - GVAX, licensed to Aduro Biotech. |
|
|
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera |
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Halozyme |
Other Relationship - FibroGen |
|
|
Other Relationship - Abbvie (Inst); Amgen Foundation (Inst); AngioDynamics (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Elstar Therapeutics (Inst); ERYTECH Pharma (Inst); FibroGen (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunovia (Inst); Interpace Diagnostics (Inst); Ipsen (Inst); Janssen Research & Development (Inst); Johnson & Johnson (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck Sharp & Dohme (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); SERVIER (Inst); Takeda (Inst); Tempus (Inst); TriSalus Life Sciences (Inst); TYME (Inst) |
|
|
|
|
Stock and Other Ownership Interests - Perthera |
Patents, Royalties, Other Intellectual Property - Perthera |
|
|
|
Stock and Other Ownership Interests - Perthera |
Consulting or Advisory Role - Perthera |
Patents, Royalties, Other Intellectual Property - Perthera |
|
|
Stock and Other Ownership Interests - Perthera |
Consulting or Advisory Role - Perthera |
Travel, Accommodations, Expenses - Perthera |
|
|
Leadership - Ceres Nanosciences; Perthera |
Stock and Other Ownership Interests - Ceres Nanosciences; Perthera; Theralink |
Consulting or Advisory Role - Ceres Nanosciences; Perthera; Theralink |
Research Funding - Abbvie (Inst); Ceres Nanosciences (Inst); G1 Therapeutics (Inst); Genentech (Inst); Mirati Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - NIH Patents Licensing Fee Distribution/Royalty; University assigned patent licensing fee/royalty |
Travel, Accommodations, Expenses - Ceres Nanosciences; Perthera |
|
|
Stock and Other Ownership Interests - Perthera |
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Foundation Medicine; Merck; Novartis; Perthera; Pfizer |
Research Funding - Arcus Biosciences (Inst); Pfizer (Inst); Seagen (Inst); Tesaro (Inst) |
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); BMS (I); Pfizer (I) |
Consulting or Advisory Role - Daichi Sanyo |
Research Funding - Advenchen Laboratories (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); The Academic GI Cancer Consortium (Inst); TRACON Pharma (Inst) |